TIRZEPATIDE 10MG

GLP2-T is a dual agonist research peptide targeting the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, representing a novel dual-incretin–based molecular design. This peptide integrates both GLP-1 and GIP signaling mechanisms into a single construct, enabling investigation of coordinated receptor activation involved in insulinotropic signaling, glucagon modulation, gastric motility regulation, and central satiety pathways as observed in controlled research models.

Summary, GLP 2-T represents an advanced dual-incretin research peptide developed to support scientific investigation into intestinal architecture, metabolic signaling pathways, and endocrine–gut axis interactions. In experimental settings, its molecular configuration has been utilized to study receptor crosstalk, peptide stability, and downstream signaling dynamics. The peptide is characterized by enhanced stability, defined receptor selectivity, and batch-to-batch reproducibility, making it suitable for controlled laboratory research involving complex physiological and biochemical systems.

GLP 2-T is manufactured as a high-purity, LPS-free peptide, verified as an endotoxin-free peptide through standardized analytical testing. As part of quality assurance protocols, research peptides endotoxin tested are employed to minimize experimental variability and ensure reliability in sensitive in-vitro and ex-vivo research applications.

GLP2-T peptide is intended strictly for research and laboratory use only. Not for human or animal use. Not for clinical, diagnostic, or therapeutic applications.